Wall Street brokerages predict that MEDNAX Inc (NYSE:MD) will post earnings per share of $0.84 for the current fiscal quarter, according to Zacks. Eight analysts have provided estimates for MEDNAX’s earnings, with the lowest EPS estimate coming in at $0.80 and the highest estimate coming in at $0.87. MEDNAX reported earnings of $0.87 per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 3.4%. The business is expected to announce its next quarterly earnings report on Thursday, November 7th.
According to Zacks, analysts expect that MEDNAX will report full year earnings of $3.04 per share for the current fiscal year, with EPS estimates ranging from $2.97 to $3.13. For the next financial year, analysts expect that the business will report earnings of $3.27 per share, with EPS estimates ranging from $3.03 to $3.54. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover MEDNAX.
MEDNAX (NYSE:MD) last posted its quarterly earnings results on Thursday, August 1st. The company reported $0.89 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.11. MEDNAX had a negative net margin of 3.53% and a positive return on equity of 9.34%. The company had revenue of $868.31 million for the quarter, compared to the consensus estimate of $868.71 million. During the same period last year, the company posted $1.07 EPS. The firm’s quarterly revenue was up .4% compared to the same quarter last year.
MD has been the subject of a number of research reports. Credit Suisse Group dropped their price objective on shares of MEDNAX from $30.00 to $28.00 and set an “outperform” rating for the company in a report on Tuesday, August 27th. Bank of America lowered shares of MEDNAX from a “neutral” rating to an “underperform” rating and set a $19.00 price objective for the company. in a report on Friday, September 6th. Zacks Investment Research lowered shares of MEDNAX from a “hold” rating to a “sell” rating and set a $26.00 price objective for the company. in a report on Wednesday, July 3rd. UBS Group dropped their price objective on shares of MEDNAX to $20.00 and set a “sell” rating for the company in a report on Wednesday, July 24th. Finally, BMO Capital Markets dropped their price objective on shares of MEDNAX from $32.00 to $25.00 and set a “market perform” rating for the company in a report on Monday, August 5th. Four research analysts have rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $28.30.
In other news, Director Md Pascal J. Goldschmidt sold 5,000 shares of MEDNAX stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $20.81, for a total value of $104,050.00. Following the completion of the sale, the director now owns 15,821 shares in the company, valued at approximately $329,235.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Michael Fernandez acquired 64,242 shares of the stock in a transaction dated Thursday, August 8th. The stock was bought at an average price of $21.68 per share, with a total value of $1,392,766.56. Following the purchase, the director now directly owns 164,530 shares in the company, valued at $3,567,010.40. The disclosure for this purchase can be found here. 3.40% of the stock is currently owned by company insiders.
Several large investors have recently added to or reduced their stakes in the company. Quadrant Capital Group LLC grew its position in MEDNAX by 538.6% in the 1st quarter. Quadrant Capital Group LLC now owns 1,009 shares of the company’s stock valued at $26,000 after purchasing an additional 851 shares during the period. Bremer Bank National Association acquired a new stake in MEDNAX in the 1st quarter valued at $30,000. Meeder Asset Management Inc. acquired a new stake in MEDNAX in the 2nd quarter valued at $36,000. Twin Tree Management LP grew its position in MEDNAX by 637.7% in the 1st quarter. Twin Tree Management LP now owns 4,242 shares of the company’s stock valued at $115,000 after purchasing an additional 3,667 shares during the period. Finally, US Bancorp DE grew its position in MEDNAX by 38.5% in the 2nd quarter. US Bancorp DE now owns 5,657 shares of the company’s stock valued at $142,000 after purchasing an additional 1,572 shares during the period. Institutional investors own 92.30% of the company’s stock.
Shares of NYSE MD opened at $23.88 on Friday. The company has a 50 day simple moving average of $21.95 and a 200 day simple moving average of $26.03. The firm has a market cap of $1.94 billion, a PE ratio of 6.80, a price-to-earnings-growth ratio of 0.89 and a beta of 0.73. MEDNAX has a 1 year low of $19.93 and a 1 year high of $48.77. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.23 and a quick ratio of 2.23.
MEDNAX Company Profile
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.
Read More: Google Finance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.